InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of HKD 21.33 billion. The enterprise value is 15.58 billion.

Market Cap	21.33B
Enterprise Value	15.58B

Important Dates

The last earnings date was Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has decreased by -0.67% in one year.

Current Share Class	n/a
Shares Outstanding	1.76B
Shares Change (YoY)	-0.67%
Shares Change (QoQ)	-14.59%
Owned by Insiders (%)	21.37%
Owned by Institutions (%)	35.93%
Float	1.38B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.86
PB Ratio	2.97
P/TBV Ratio	3.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-33.23
EV / Sales	14.50
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-32.99

Financial Position

The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.23.

Current Ratio	7.45
Quick Ratio	7.01
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-3.55
Interest Coverage	-16.12

Financial Efficiency

Return on equity (ROE) is -6.50% and return on invested capital (ROIC) is -3.97%.

Return on Equity (ROE)	-6.50%
Return on Assets (ROA)	-3.52%
Return on Invested Capital (ROIC)	-3.97%
Return on Capital Employed (ROCE)	-6.52%
Revenue Per Employee	986,434
Profits Per Employee	-430,587
Employee Count	1,089
Asset Turnover	0.10
Inventory Turnover	1.29

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +149.29% in the last 52 weeks. The beta is 1.03, so InnoCare Pharma's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+149.29%
50-Day Moving Average	8.60
200-Day Moving Average	6.45
Relative Strength Index (RSI)	67.46
Average Volume (20 Days)	15,538,302

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of HKD 1.07 billion and -468.91 million in losses. Loss per share was -0.28.

Revenue	1.07B
Gross Profit	926.90M
Operating Income	-579.67M
Pretax Income	-481.64M
Net Income	-468.91M
EBITDA	-508.34M
EBIT	-579.67M
Loss Per Share	-0.28

Full Income Statement

Balance Sheet

The company has 7.45 billion in cash and 1.68 billion in debt, giving a net cash position of 5.77 billion or 3.28 per share.

Cash & Cash Equivalents	7.45B
Total Debt	1.68B
Net Cash	5.77B
Net Cash Per Share	3.28
Equity (Book Value)	7.18B
Book Value Per Share	4.06
Working Capital	7.21B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -389.01 million and capital expenditures -83.25 million, giving a free cash flow of -472.26 million.

Operating Cash Flow	-389.01M
Capital Expenditures	-83.25M
Free Cash Flow	-472.26M
FCF Per Share	-0.27

Full Cash Flow Statement

Margins

Gross margin is 86.29%, with operating and profit margins of -53.96% and -43.65%.

Gross Margin	86.29%
Operating Margin	-53.96%
Pretax Margin	-44.84%
Profit Margin	-43.65%
EBITDA Margin	-47.32%
EBIT Margin	-53.96%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.67%
Shareholder Yield	0.67%
Earnings Yield	-2.20%
FCF Yield	-2.21%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCare Pharma has an Altman Z-Score of 2.25. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.25
Piotroski F-Score	n/a